Dr. David Samadi’s Prostate Cancer Center Offers Biomarker Diagnostic Testing for Prostate Cancer

Dr. David Samadi’s Prostate Cancer Center Offers Biomarker Diagnostic Testing for Prostate Cancer

NEW YORK, NY – (PR Newswire – June 23, 2015) –World renowned robotic prostate surgeon, Dr. David Samadi, is now offering a full new suite of Biomarker Diagnostic Testing for diagnosing prostate cancer.

Dr. Samadi’s Prostate Cancer Center will be offering a range of diagnostic tests for assessing the risk and optimizing the diagnosis of prostate cancer to further indicate the need for a biopsy.

“We’re very pleased to offer these revolutionary diagnostic tests to our patients. These new testing methods are making for smarter diagnosis of prostate cancer, which then leads to the right treatment for each patient. This is a major shift in this field, especially when it comes to distinguishing between aggressive and low-grade cancers,” said Dr. Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City.

The game changer here is the role genetic testing plays throughout the entire process, from diagnosis to recurrence. If a man’s PSA is elevated, the 4K ScorePCA3, and advanced MRI can further indicate activity around the prostate as well as support whether to get a biopsy or not.

Dr. Samadi’s Prostate Cancer Center will offer the following diagnostic tests:

PSA Blood Test: PSA stands for prostate specific antigen. It is a protein produced by cells in the prostate gland. A PSA test is a simple blood test that measures how much PSA there is in a man’s blood. The blood test is then sent to a laboratory to be analyzed. The results of the PSA may be the first indicator of prostate cancer.

4K Score: This test measures four prostate-specific kallikreins in the blood: Total PSA, FREE PSA, Intact PSA and Human Kallikrein 2 (hK2). Results are combined with patient age, digital rectal exam (nodule, no nodule) and prior negative biopsy results (yes, no). The tests then provides a % probability on a scale of 1%-95% for the patient having high-grade prostate cancer. The 4K Score is designed specifically to reduce the number of unnecessary negative biopsies that detect low-grade cancer. This means not all men who have an elevated PSA will require a biopsy.

PCA3 Score: This is a simple urine sample collected following a digital rectal exam for the determination of the PCA3 score. Specific for prostate cancer, and, unlike the PSA, this test is not affected by prostate enlargement or other non-cancerous prostate conditions. In combination with PSA and DRE results, the PCA3 score provides useful information to help decide if a biopsy is needed, or can be delayed. It’s much more specific in giving additional information about the aggressiveness of the cancer if the patient has a positive biopsy.

MRI Guided Biopsy: Dr. Samadi’s Prostate Cancer Center is the only center in New York City using the revolutionary Uronav Fusion Biopsy System for MRI-Guided Biopsy. An MRI-ultrasound fusion biopsy involves taking an MRI and then fusing the data with real-time ultrasound images for guidance on biopsy procedures. The UroNav System combines electromagnetic tracking and navigation with an onboard computer and a real-time imaging interface in one mobile workstation. The MR/Ultrasound fusion aligns and registers prior diagnostic MR images with real-time ultrasound images.

“Now that we’ve moved from Ultrasound to MRI, in combination with smarter diagnostic testing methods, we may actually be to able crack the code and diagnose aggressive prostate cancer earlier. And of course, this leads to the right treatment for each patient,” said Dr. Samadi.

Patients newly diagnosed with prostate cancer or an elevated PSA can contact Dr. David Samadi’s center, for a consultation. Visit ProstateCancer911.com and call 212.365.5000 to set up your consultation.